HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Tango Therapeutics (NASDAQ:TNGX) and maintained an $11 price target.
August 08, 2023 | 10:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tango Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $11.
The reiteration of a 'Buy' rating and maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. This could potentially lead to increased investor confidence and a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100